Histopathological characterization of the skeletal myopathy in rasH2 mice carrying human prototype c-Ha-ras gene.

J Vet Med Sci

Toxicology Laboratory, Pharmaceuticals Research Center, Mitsubishi Pharma Corporation, 1-1-1 Kazusakamatari, Kisarazu, Chiba 292-0818, Japan.

Published: May 2005

A skeletal myopathy is found in approximately 100% of rasH2 mice. To confirm detailed features of the rasH2 skeletal myopathy, the biceps femoris, diaphragm, triceps brachii, gastrocnemial (types I and II fiber-mixed muscles) and soleus muscle (type I fiber-dominant muscle) obtained from male rasH2 and non-transgenic littermates aged 10-13 and 34 weeks were examined. Variations in the muscle fiber size, early-scattered degeneration/necrosis and regeneration of muscle fibers were detected in 10-13-week-old rasH2 mice. The severity of the above muscular lesions was more prominent in older rasH2 mice. These lesions were noted in the type II myofiber dominant muscles (biceps femoris, triceps brachii and gastrocnemial). NADH-TR stain clearly demonstrated a disorganized intermyofibrillar network and necrotic change in muscle fibers. No specific morphological changes, like rod structure or tubular aggregation seen in some types of myopathy, were noted in Gomori trichrome and NADH-TR stains in the rasH2 mouse like in many types of muscular dystrophy. Electronmicroscopically, occasional muscle fiber degeneration/regeneration, invaded phagocytic cells, indistinct Z-band suggesting excessive contraction and dilatation of the sarcoplasmic reticulum were observed. In summary, the skeletal myopathy occurring in rasH2 mice is consistent with muscular dystrophy characterized morphologically by progressive degeneration and regeneration of myofibers. The myopathy is confined to the type II myofiber predominant muscles and is not associated with any pathognomonic lesions. These characteristics will provide us with a useful model for research in muscular dystrophy of diverse myofibers.

Download full-text PDF

Source
http://dx.doi.org/10.1292/jvms.67.481DOI Listing

Publication Analysis

Top Keywords

rash2 mice
20
skeletal myopathy
16
muscular dystrophy
12
rash2
8
biceps femoris
8
triceps brachii
8
brachii gastrocnemial
8
muscle fiber
8
muscle fibers
8
type myofiber
8

Similar Publications

Article Synopsis
  • Inotersen is an approved drug for hereditary transthyretin-mediated amyloidosis (hATTR), evaluated through various nonclinical safety studies to assess its effects and risks.
  • In studies involving Tg.rasH2 mice and Sprague Dawley rats, no treatment-related tumors were found, although some proinflammatory effects and kidney issues were noted.
  • Overall, the data suggest that while there are side effects linked to Inotersen, there is insufficient evidence to classify it as carcinogenic, particularly concerning its relevance to human health.
View Article and Find Full Text PDF

Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir.

Toxicol Sci

December 2024

Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, Merck & Co. Inc., Rahway, NJ 07065, United States.

Molnupiravir is registered or authorized in several countries as a 5-d oral coronavirus disease 2019 treatment for adults. Molnupiravir is a prodrug of the antiviral ribonucleoside β-D-N4-hydroxycytidine (NHC) that distributes into cells, where it is phosphorylated to its pharmacologically active ribonucleoside triphosphate (NHC-TP) form. NHC-TP incorporates into severe acute respiratory syndrome coronavirus 2 RNA by the viral RNA-dependent RNA polymerase, resulting in an accumulation of errors in the viral genome, leading to inhibition of viral replication and loss of infectivity.

View Article and Find Full Text PDF

Alpha-glycosyl isoquercitrin (AGIQ) is composed of isoquercitrin and its glucosylated derivatives and has many biological activities, including anti-inflammatory, antioxidant, and anti-cancer properties. However, the effect of AGIQ administered orally on gut microbiota composition remains unclear. The objective of this study was to evaluate the effect of AGIQ on the gut microbiota of animals in different dose groups.

View Article and Find Full Text PDF

Enarodustat (JTZ-951) is an oral hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor for the treatment of anemia with chronic kidney disease. Carcinogenicity of enarodustat was evaluated in a 26-week repeated oral dose study in Transgenic rasH2 (Tg.rasH2) mice and a 2-year repeated oral dose study in Sprague-Dawley (SD) rats.

View Article and Find Full Text PDF
Article Synopsis
  • * Some research reveals conflicting views on how activating a pathway (HIF) may influence tumor development, with some suggesting it helps tumors grow and others suggesting it may reduce tumor growth.
  • * In studies on transgenic mice and rats receiving various doses of vadadustat over extended periods, the tumors found were deemed statistically unrelated to the treatment, suggesting that vadadustat does not have a carcinogenic effect in these animals.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!